Results 111 to 120 of about 6,465,161 (268)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Progression-free survival analysis.

, 2014
Kaplan-Meier curves for progression-free survival according to ALK status: increase of gene copy number vs. disomic status.
Ilaria Bossi (545437), Claudia Maggi (545430), Maria Di Bartolomeo (545431), Filippo de Braud (545440), Giuseppe Pelosi (234010), Roberto Iacovelli (545435), Adele Testi (545434), Giorgia Leone (545438), Rosalba Miceli (545436), Massimo Milione (545439), Federica Perrone (545433), Filippo Pietrantonio (545429), Maria Grazia Facciorusso (545432)   +12 more
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis

Oncology Reviews
Background:Malignant gliomas are known with poor prognosis and low rate of survival among brain tumors. Resection surgery is followed by chemotherapy and radiotherapy in treatment of gliomas which is known as the conventional treatment.
Elnaz Amanzadeh Jajin, Saeed Oraee Yazdani, Alireza Zali, Abolghasem Esmaeili   +3 more
doaj   +1 more source

Progression-free and overall survival for AT-101 monotherapy in patients with recurrent glioblastoma (NABTT 0702).

Progression-free and overall survival for AT-101 monotherapy in patients with recurrent glioblastoma (NABTT 0702).
Joy Fisher (17867121), Stuart Grossman (4765017), Xiaobu Ye (596796), Lance Leopold (6492332), Louis B. Nabors (6743576), John B. Fiveash (17867112), Serena Desideri (14988018), David M. Peerboom (17867115), Glenn J. Lesser (14931569), Tom Mikkelsen (95018), Sajeel Chowdhary (15032564), Myrna Rosenfeld (17867118)   +11 more
core   +1 more source

Progression-free survival according to pre-therapy and follow-up NLR at 12 weeks of enzalutamide treatment.

, 2016
Progression-free survival according to pre-therapy and follow-up NLR at 12 weeks of enzalutamide treatment.
Lisa Derosa (2605687), Cristian Lolli (3150675), Emanuela Scarpi (382324), Orazio Caffo (3150690), Sunnya Zarif (3150678), Vincenza Conteduca (3150663), Gianmauro Numico (591004), Francesco Massari (295545), Tony Elliott (3150687), Robert J. Jones (3150666), Paolo Fabbri (3150681), Catherine Hanna (3150669), Helen Joyce (3150672), Simon J. Crabb (1923172), Ugo De Giorgi (2605693), Francesca Maines (3150684)   +15 more
core   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

The role of dexamethasone during treatment phases in glioblastoma: Insights from a retrospective observational study

Brain and Spine
Background: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. Dexamethasone (DEX) is commonly used to manage peritumoral edema, but its impact on overall survival (OS) and progression-free survival (PFS) remains unclear across ...
Juliane Göbel, Maximilian Scheer, Clemens Kirchner, Sandra Leisz, Julian Prell, Christian Strauss, Sebastian Simmermacher, Stefan Rampp   +7 more
doaj   +1 more source

Forest plot for progression-free survival.

, 2016
Forest plot for progression-free survival.
Lisa Derosa (2605687), Cristian Lolli (3150675), Emanuela Scarpi (382324), Orazio Caffo (3150690), Sunnya Zarif (3150678), Vincenza Conteduca (3150663), Gianmauro Numico (591004), Francesco Massari (295545), Tony Elliott (3150687), Robert J. Jones (3150666), Paolo Fabbri (3150681), Catherine Hanna (3150669), Helen Joyce (3150672), Simon J. Crabb (1923172), Ugo De Giorgi (2605693), Francesca Maines (3150684)   +15 more
core   +1 more source